Correction to: Scientific Reports https://doi.org/10.1038/s41598-022-15668-8, published online 09 July 2022
The original version of this Article contained errors, where a study participant was omitted in the mild COVID-19 experimental group for “bulk” analysis. As the result, in the Results, under ‘A clinical cohort to study early COVID-19 with mild or moderate symptoms’,
“Subjects with mild symptoms exhibited a mean score of 12.9 ± 2.1 and 12.2 ± 2.8 for total PBMC assays (bulk) and assays of individual PBMCs (single-cell assays), respectively, which corresponded to the World Health Organization (WHO) Ordinal 8-point scale 1 (OS1, ambulatory and with no limitation of activities).”
now reads:
“Subjects with mild symptoms exhibited a mean score of 12.8 ± 1.9 and 12.2 ± 2.8 for total PBMC assays (bulk) and assays of individual PBMCs (single-cell assays), respectively, which corresponded to the World Health Organization (WHO) Ordinal 8-point scale 1 (OS1, ambulatory and with no limitation of activities).”
In Table 1, in column ‘Mild disease’, the 'Number of subjects', 'Sex (male/female)' and ‘Max severity score (± SE)’ have been corrected. The correct and incorrect values are listed below.
Incorrect:
Characteristics | Mild disease |
|---|---|
Number of subjects | 7 |
Sex (male/female) | 4/3 |
Max severity score (± SE) | 12.9 ± 2.1 |
Correct:
Characteristics | Mild disease |
|---|---|
Number of subjects | 8 |
Sex (male/female) | 5/3 |
Max severity score (± SE) | 12.8 ± 1.9 |
Additionally, the same error occurred in Supplementary Information Figure S1 and Supplementary Table S1.
The original Supplementary Figure S1 and accompanying legend appear below.
(A) Symptom severity sums for the subjects profiled with bulk assays and (B) severity scores for each reported symptom for the subjects profiled with bulk assays. (C) Symptom severity sums for subjects profiled with single-cell assays and (D) severity scores for each reported symptom for the subjects profiled with single-cell assays. For both cohorts, the sum of severity scores for all reported symptoms are shown for close contacts (green), COVID-19 subjects with mild symptoms (blue), and with moderate symptoms (orange).
A new row has been added to Table S1. It now reads:
Group | Alias ID | Race | Ethnicity | Day of PBMC collection | PCR | Serology Test (IgG) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mild | 7085CA | White | Non-Hispanic | 0 | 7 | 14 | N‡ | N | N | N | N | P |
The original Article and Supplementary Information files have been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Giroux, N.S., Ding, S., McClain, M.T. et al. Author Correction: Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion. Sci Rep 13, 6462 (2023). https://doi.org/10.1038/s41598-023-33323-8
Published:
DOI: https://doi.org/10.1038/s41598-023-33323-8
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
